Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kiyotoshi Imai

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Blood|March 5, 2014
Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemiaShuichi Mizuta, Keitaro Matsuo, Satoshi Nishiwaki, et al.
American Journal of Hematology|January 20, 2017
Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemiaShin Fujisawa, Shuichi Mizuta, Hideki Akiyama, et al.
Transfusion|September 19, 2008
Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol)Hiroshi Azuma, Junichi Hirayama, Mitsuaki Akino, et al.
International Journal of Hematology|March 29, 2014
JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in JapanYoko Edahiro, Soji Morishita, Kochi Takahashi, et al.
International Journal of Hematology|November 24, 2020
Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study GroupTakeshi Saito, Yoshihiro Hatta, Fumihiko Hayakawa, et al.
Transplantation and Cellular Therapy|December 7, 2021
Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete RemissionShinichi Kako, Fumihiko Hayakawa, Koichi Miyamura, et al.
International Journal of Hematology|July 30, 2021
Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapyShinichi Kako, Fumihiko Hayakawa, Kiyotoshi Imai, et al.
International Journal of Hematology|November 2, 2015
Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral bloodKunio Kitamura, Takahiro Nishiyama, Ken Ishiyama, et al.
Annals of Hematology|September 26, 2018
Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 studyNaomi Kawashima, Akimi Akashi, Yasunobu Nagata, et al.
Leukemia Research|January 24, 2018
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 studyYasuhiko Harada, Yasunobu Nagata, Rika Kihara, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Blood|March 5, 2014
Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemiaShuichi Mizuta, Keitaro Matsuo, Satoshi Nishiwaki, et al.
American Journal of Hematology|January 20, 2017
Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemiaShin Fujisawa, Shuichi Mizuta, Hideki Akiyama, et al.
Transfusion|September 19, 2008
Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol)Hiroshi Azuma, Junichi Hirayama, Mitsuaki Akino, et al.
International Journal of Hematology|March 29, 2014
JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in JapanYoko Edahiro, Soji Morishita, Kochi Takahashi, et al.
International Journal of Hematology|November 24, 2020
Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study GroupTakeshi Saito, Yoshihiro Hatta, Fumihiko Hayakawa, et al.
Transplantation and Cellular Therapy|December 7, 2021
Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete RemissionShinichi Kako, Fumihiko Hayakawa, Koichi Miyamura, et al.
International Journal of Hematology|July 30, 2021
Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapyShinichi Kako, Fumihiko Hayakawa, Kiyotoshi Imai, et al.
International Journal of Hematology|November 2, 2015
Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral bloodKunio Kitamura, Takahiro Nishiyama, Ken Ishiyama, et al.
Annals of Hematology|September 26, 2018
Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 studyNaomi Kawashima, Akimi Akashi, Yasunobu Nagata, et al.
Leukemia Research|January 24, 2018
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 studyYasuhiko Harada, Yasunobu Nagata, Rika Kihara, et al.
Pageof 3